Actively Recruiting
SLV-154 Treatment of Metastatic Solid Tumors
Led by Solve Therapeutics · Updated on 2026-01-23
70
Participants Needed
9
Research Sites
98 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.
CONDITIONS
Official Title
SLV-154 Treatment of Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men or women aged 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Histologically or cytologically confirmed diagnosis of one of the following solid tumors: squamous cell cancer of head and neck, non-small cell lung cancer, small cell lung cancer, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, urothelial cancer, sarcoma, or thyroid cancer
- Presence of metastatic disease that has progressed during or after previous treatment
- Radiographically measurable disease
- Prior treatment with commercially available therapies indicated for the cancer type that have demonstrated survival benefit
- Availability of tumor tissue from a recent biopsy or archival sample
- Availability of CT, MRI, or PET/CT imaging within 35 days before starting study drug
- Completion of all previous cancer therapies at least 1 week before starting study drug
- Adequate blood counts, coagulation, liver, and kidney function
- Negative viral tests or adequate therapy for HIV, hepatitis B, and hepatitis C
- For females of childbearing potential, a negative pregnancy test and willingness to use contraception from screening until 6 months after final dose
- For males who can father children and have partners of childbearing potential not using adequate contraception, willingness to use contraception from study start until 6 months after final dose and to refrain from sperm donation until 12 months after final dose
- Willingness and ability to comply with study visits, drug administration, laboratory tests, tumor biopsies, imaging, and study restrictions
- Signed informed consent indicating understanding of the experimental nature of the therapy and study procedures
You will not qualify if you...
- Central nervous system cancer unless brain metastases have been treated, stable for at least 4 weeks, and no corticosteroids needed
- Another cancer that could affect safety, longevity, drug interactions, or study results
- Uncontrolled bacterial, fungal, or viral infections at study start
- Significant cardiovascular events or conditions
- Significant abnormalities on screening ECG
- Pregnancy or breastfeeding
- Major surgery within 4 weeks before starting study drug
- Use of strong inhibitors or inducers of CYP3A4 or CYP1A2 enzymes
- Use of drugs known to prolong QT interval within 7 days before starting study drug
- Participation in another therapeutic or imaging clinical trial
- Other conditions likely to interfere with study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States, 92663
Actively Recruiting
2
Washington University
St Louis, Missouri, United States, 63110
Actively Recruiting
3
Astera Cancer Care
East Brunswick, New Jersey, United States, 08816
Actively Recruiting
4
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
5
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
6
Oncology Consultants
Houston, Texas, United States, 77030
Actively Recruiting
7
Mays Cancer Center; University of Texas Health San Antonio
San Antonio, Texas, United States, 78229
Actively Recruiting
8
University of Washington / Fred Hutchinson Cancer Center
Seattle, Washington, United States, 98109
Actively Recruiting
9
Northwest Medical Specialties, PLLC
Tacoma, Washington, United States, 98405
Actively Recruiting
Research Team
H
Hong Ren, MD
CONTACT
L
Langdon L Miller, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
8
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here